Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Type:
Grant
Filed:
June 25, 2002
Date of Patent:
April 13, 2010
Assignee:
Genentech, Inc.
Inventors:
Kevin P. Baker, Jian Chen, Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, James Pan, Victoria Smith, Colin K. Watanabe, William I. Wood, Zemin Zhang
Abstract: The invention relates to the identification and isolation of DNAs encoding the human Toll proteins PR0285, PR0286, and PR0358, and to methods and means for the recombinant production of these proteins. The invention also concerns antibodies specifically binding the PR0285, or PR0286, or PR0358 Toll protein.
Type:
Grant
Filed:
October 7, 1998
Date of Patent:
April 13, 2010
Assignee:
Genentech, Inc.
Inventors:
Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Melanie R. Mark, Ruey-Bing Yang
Abstract: DNAs are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Grant
Filed:
September 27, 2006
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
Abstract: The present invention relates to nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing, and immunoadhesions and antibodies to mammalian GFR?3, a novel ?-subunit receptor of the GDNF (i.e. GFR) receptor family. It further relates to an assay for measuring activation of an ?-subunit receptor by detecting tyrosine kinase receptor activation (i.e., autophosphorylation) or other activities related to ligand-induced ?-subunit receptor homo-dimerization or homo-oligomerization.
Type:
Grant
Filed:
September 27, 2006
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
Frederic J. de Sauvage, Robert D. Klein, Heidi S. Phillips, Arnon Rosenthal
Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.
Type:
Grant
Filed:
October 5, 2006
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
Frederic de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne S. Hongo, Victoria Smith
Abstract: Methods for producing membrane-spanning polypeptides in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents, as well as use of promoters and expression vectors for expressing high yields of membrane-spanning polypeptides in bacterial cells. Mutated promoters provide tight control of membrane-spanning polypeptides in bacterial cell hosts.
Type:
Grant
Filed:
December 22, 2005
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
James A. Ernst, Daniel Yansura, Hok Seon Kim
Abstract: GDNFR?, GDNFR? extracellular domain (ECD), GDNFR? variants, chimeric GDNFR? (e.g., GDNFR? immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to GDNFR?-ligands, for example GDNF, by providing GDNFR? to the cell. Also provided are methods for using GDNFR?, GDNF, or agonists thereof, separately or in complex, to treat kidney diseases.
Type:
Grant
Filed:
January 20, 2006
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
Robert D. Klein, Mark W. Moore, Arnon Rosenthal, Anne M. Ryan
Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.
Type:
Grant
Filed:
October 19, 2006
Date of Patent:
April 6, 2010
Assignee:
Genentech, Inc.
Inventors:
Germaine Fuh, Hans-Peter Gerber, Wei-Ching Liang, Frederic A. Fellouse, Sachdev S. Sidhu, Christian Wiesmann
Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.
Abstract: Methods for producing membrane-spanning polypeptides in high yields, with native conformation, and/or in soluble form include solubilizing in non-ionic or zwitterionic detergents, as well as use of promoters and expression vectors for expressing high yields of membrane-spanning polypeptides in bacterial cells. Mutated promoters provide tight control of membrane-spanning polypeptides in bacterial cell hosts.
Type:
Application
Filed:
August 14, 2009
Publication date:
April 1, 2010
Applicant:
Genentech, Inc.
Inventors:
James A. ERNST, Daniel Yansura, Hok Seon Kim
Abstract: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
Type:
Application
Filed:
October 14, 2008
Publication date:
April 1, 2010
Applicant:
Genentech, Inc.
Inventors:
Avi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jim Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or degenerative cartilagenous disorders, including arthritis, comprising the administration of WISP polypeptide. Optionally, the administration may be in combination with one or more cartilage agents (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor). Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of WISP polypeptide in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or degenerative cartilagenous disorders comprising the administration of chondrocytes previously treated with an effective amount of WISP polypeptide.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
March 30, 2010
Assignee:
Genentech, Inc,
Inventors:
Luc Desnoyer, Ellen H. Filvaroff, Diane Pennica
Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
Type:
Grant
Filed:
May 26, 2006
Date of Patent:
March 23, 2010
Assignee:
Genentech, Inc.
Inventors:
James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
Abstract: Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
Type:
Application
Filed:
July 31, 2009
Publication date:
March 18, 2010
Applicant:
Genentech, Inc.
Inventors:
Philippe Bergeron, Frederick Cohen, Anthony Estrada, Michael F.T. Koehler, Kevin Hon Luen Lau, Cuong Ly, Joseph P. Lyssikatos, Daniel Ortwine, Zhonghua Pei, Xianrui Zhao
Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.